Turn Therapeutics to present at Stifel forum
The company said it will present updated atopic dermatitis data and a pruritus-focused Stage 2 enrichment strategy at Stifel 2026.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Turn Therapeutics to Present at Stifel 2026 Virtual Immunology and Inflammation Forum
Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted, localized therapies for inflammatory skin diseases, today announced that Bradley Burnam, Chief Executive Officer, and Stephen M. Hahn, M.D., Executive Clinical and Regulatory Lead, will present at the…